v0.5.1: disable apply_patch in agents prone to append-mode failures

Root cause: apply_patch finds anchor lines in read-cached file state,
but file may have been modified between read and patch, causing stalls.

Changes:
- dr-verifier: disable apply_patch AND edit; force read-then-write protocol for evidence file appends
- dr-analyst: document write-preferred protocol for sources.jsonl appends
- dr-polisher: disable apply_patch; keep edit for small string replacements
- dr-editor-in-chief / dr-translator: disable apply_patch

Recovery procedure documented in dr-verifier for write failures.

projects/dual-target-rnai-pipeline-2026/phase1/framework.md

@@ -0,0 +1,402 @@
+# 双靶点 RNAi 药物工艺图谱与上游供应链机会研究
+
+**副标题**：近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）
+
+**英文主标题（Working Title, EN）**：*Dual-Target RNAi Drug Process Atlas and Upstream Supply-Chain Opportunity Map*
+**副标题（EN）**：*Decoding Synthesis, Conjugation, and Enzyme-Catalysis Pathways across the Global Pipeline, 2021–2026*
+
+---
+
+## 元信息 / Meta
+
+| 字段 | 值 |
+|---|---|
+| 研究类型 | 综述（Review，扩至 detailed 档下限） |
+| 字数模式 | auto → 用户要求"往上加 + 技术锚点锐化" |
+| 目标字数 | **≈ 15,000 EN words / 21,000 ZH chars**（下限 12,000 EN / 17,000 ZH） |
+| 核心受众 | 上游供应链研发团队（工业用酶 / 无细胞表达 / 固定化酶催化 / QC 酶 / 单体-载体方向） |
+| 时间范围 | 近 5 年（2021-01 至 2026-04） |
+| 地理范围 | 全球对比（中美欧日为主） |
+| 工作语言 | English（Phase 2-3） |
+| 输出语言 | 中文（Phase 4 翻译） |
+| 章节数 | **10 章**（含引言与结论） |
+
+### 核心问题 / Core Questions
+
+**中文：**
+1. 近 5 年全球与中国在研的双靶点 RNAi 药物管线有哪些？采用何种靶点组合、技术平台与开发阶段？
+2. 双靶点 siRNA 的分子设计路径（串联 / 偶联 / cocktail / 多价支架）有哪些？工艺差异与关键壁垒？
+3. 双靶点 siRNA 的合成、偶联、QC 工艺在各家管线中的实现方式有何不同？
+4. 序列合成、偶联化学、QC 酶、纯化等环节上，上游供应链存在哪些国产替代与卡位机会？
+5. 哪些双靶点 RNAi 技术路线最可能率先商业化？对应的上游供应机会窗口与技术锚点？
+
+**English:**
+1. What dual-target RNAi assets are in active development globally and in China over 2021-2026?
+2. What molecular design paradigms (tandem / covalent / cocktail / multivalent scaffold) define dual-target siRNA, and what process differences and bottlenecks do they impose?
+3. How do synthesis, conjugation, and QC workflows vary across global and Chinese pipelines?
+4. At which supply-chain nodes (industrial enzymes, immobilized catalysis, cell-free systems, phosphoramidite monomers, GalNAc ligands, solid supports, QC enzymes) do domestic-substitution and disruptive opportunities exist?
+5. Which dual-target technical routes are most likely to reach commercial scale first, and which upstream entry points offer the largest opportunity windows — with what technical thresholds?
+
+### 禁区 / Exclusions
+
+- 不展开适应症与临床有效性细节（临床进度仅作为管线标签）
+- 不涉及 mRNA / ASO / saRNA / 基因编辑等非 siRNA 模态工艺细节
+- 不做市场估值 / 销售预测 / 投资测算
+- 不展开疾病机制与药理学讨论
+- **BIOSECURE 法案只在 Ch 9 作为背景要素一句话点到，不展开**
+
+---
+
+## Central Thesis / 全局论点
+
+**EN**: The true competitive frontier of dual-target RNAi is not the second siRNA strand but the manufacturing stack beneath it — multivalent GalNAc assembly, enzymatic ligation, immobilized biocatalysis, and the quietly scarce GMP-grade QC enzymes are the choke points that will decide which platforms reach commercial scale. Four upstream nodes — specialty phosphoramidite monomers, high-load solid supports, immobilized glycosyl-transfer biocatalysis, and sequencing/digestion/phosphatase QC enzymes — concentrate most of the opportunity for suppliers who can simultaneously meet Chinese NMPA's 2026 chemoenzymatic guidance and FDA/ICH Q11-Q13 style expectations.
+
+**中文**：双靶点 RNAi 的真正竞争前沿不是"加一条 siRNA 链"，而是其下的制造栈 — 多价 GalNAc 组装、酶法连接、固定化生物催化，以及常被忽视却持续短缺的 GMP 级 QC 酶，是决定平台能否走向规模化的工艺节点。机会集中在四个上游环节：专用亚磷酰胺单体、高载量固相载体、固定化糖基转移/酯化生物催化、寡核苷酸测序/酶切/磷酸酶等 QC 酶；能同时满足中国 NMPA 2026 化学酶连指导原则与 FDA/ICH Q11-Q13 体系要求的供应商，将获取最大的结构性红利。
+
+---
+
+## 章节大纲 / Chapter Outline
+
+### Chapter 1 / 第 1 章 — Why the Second Strand Matters Less Than the Stack Beneath It
+
+**中文标题**：双靶点的真正战场不在"加第二条链"，而在其下的制造栈
+
+- **Priority**: intro
+- **Word quota**: 1,050 EN (≈ 1,500 ZH) — 7%
+- **Core research question (EN)**: Why has the industry converged on "dual-target" as the design label, and what does that label hide about the underlying manufacturing shift?
+- **Preliminary hypothesis (EN)**: The visible innovation is molecular (second siRNA, smarter scaffold); the real bottleneck has migrated to conjugation chemistry, multivalent ligand assembly, QC-enzyme supply, and enzymatic ligation.
+- **Expected sources**: src_A01, src_A05, src_A07, src_B02, src_C01, src_C04, src_D01
+
+- **1.1** From monogenic silencing to combinatorial target logic / 从单基因沉默走到组合靶点
+  - Research thinking (EN): Map Alnylam approvals timeline + 2023-2026 pipeline density (APOC3+ANGPTL3, AGT+PCSK9, complement pairs).
+- **1.2** The manufacturing shock hidden behind that shift / 分子设计跃迁背后隐藏的工艺位移
+  - Research thinking (EN): Quantify how each design paradigm adds synthetic steps, elevates monomer diversity, and raises conjugation complexity.
+- **1.3** What this report does and why it's written for upstream suppliers / 报告逻辑与读者路径
+  - Research thinking (EN): Thesis statement, chapter roadmap, source base (63 Tier 1-2 sources indexed in `initial-scan-index.md`), methodology.
+
+---
+
+### Chapter 2 / 第 2 章 — Dual-Target Design Space Has Already Bifurcated into Four Paradigms, Each with a Different Process Signature
+
+**中文标题**：双靶点设计空间已分化为四种范式，每种都带出一条工艺签名
+
+- **Priority**: P0
+- **Word quota**: 1,500 EN (≈ 2,100 ZH) — 10%
+- **Core research question (EN)**: What are the four dominant dual-target design paradigms and which process constraints does each impose?
+- **Preliminary hypothesis (EN)**: Covalent-linker, multivalent-GalNAc, di-valent scaffold, and cocktail paradigms diverge sharply in step count, monomer needs, and purification complexity.
+- **Technical hooks (for expert judgment)**:
+  - Step count per duplex (solid-phase cycles, convergent couplings)
+  - Monomer diversity index (# distinct phosphoramidites per construct)
+  - Linker cleavage trigger (disulfide, acid-labile, lysosomal, nuclease)
+  - Scaffold valency (1 / 2 / 3 / 4 / ≥5 GalNAc units)
+  - Duplex vs. multi-strand annealing complexity (how many strands to anneal under what ionic conditions)
+- **Expected sources**: src_A01, src_A02, src_A06, src_A08, src_A09, src_A10, src_A12, src_C03, src_C06
+
+- **2.1** Covalently-linked tandem siRNAs — Alnylam-style disulfide/linker route / 共价连接串联 siRNA
+  - Research thinking (EN): Deconstruct US9187746 claim scope + linker chemistry from src_A01; quantify extra deprotection/unwinding burden.
+  - Technical hooks: disulfide-bond redox window, unwinding kinetics at 37 °C, linker stability in serum > 48 h.
+- **2.2** Multivalent GalNAc clusters — scaffold as combined delivery + design unit / 多价 GalNAc 簇
+  - Research thinking (EN): Compare pyran (src_A02), ribofuranose (src_A04), diamine scaffold (src_A10); explicit on convergent-synthesis demand at valency ≥ 4.
+  - Technical hooks: ASGPR Kd by valency (nM range), cluster radius (Å), solution-state cluster integrity (CD spectroscopy).
+- **2.3** Di-valent and branched scaffolds — Khvorova/UMass programmable track / 二价与分枝支架
+  - Research thinking (EN): src_A06 di-siRNA in CNS as anchor; src_A09 branched dendritic multi-siRNA; flag that QC enzymes (nuclease P1, RNase T1) become mandatory for duplex verification.
+  - Technical hooks: scaffold symmetry, branch-point stability, serum half-life without lipid carrier.
+- **2.4** Cocktail / muRNA — Sirnaomics engineered-labile alternative / 混合 / muRNA
+  - Research thinking (EN): src_A12 GalAhead™; contrast manufacturing simplicity vs. CMC identity challenges (how do regulators define "the API" when composition is defined by ratio).
+  - Technical hooks: labile-linker cleavage T½, intracellular release kinetics, composition-ratio CV across batches.
+
+---
+
+### Chapter 3 / 第 3 章 — The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else
+
+**中文标题**：全球管线比头条更密，但中国正在以最快速度堆积资产
+
+- **Priority**: P0
+- **Word quota**: 1,500 EN (≈ 2,100 ZH) — 10%
+- **Core research question (EN)**: How many dual-target RNAi programs exist globally, what target combinations dominate, and where is China on the velocity curve?
+- **Preliminary hypothesis (EN)**: Global active pipeline ≈ 10-15 disclosed dual-target programs in Phase 1-2; China accounts for close to half of new INDs filed 2023-2026.
+- **Technical hooks**:
+  - Target combination rationale (pharmacology-driven vs. pipeline-efficiency-driven)
+  - Disclosed vs. inferred (non-disclosed) dual-target constructs
+  - Platform labels (RiboGalSTAR™, RADS, PDoV-GalNAc, branched-linker) mapped to design paradigms from Ch 2
+  - Dosing interval (single-dose / Q3M / Q6M) as proxy for chemistry maturity
+- **Expected sources**: src_A05, src_A07, src_A11, src_A13, src_A14, src_A15, src_D11, src_D12
+
+- **3.1** Disclosed global dual-target set — real pipeline vs. marketing labels / 已披露的全球双靶点集合
+  - Research thinking (EN): Cross-reference ClinicalTrials.gov + 10-K + systematic review (src_A05); remove double-counting.
+- **3.2** Target-combination clustering and why cardiometabolic owns the field / 靶点组合聚类
+  - Research thinking (EN): APOC3+ANGPTL3, AGT+PCSK9, complement pairs; explain ASGPR density on hepatocytes (~10⁶/cell) as the anatomic reason for liver monoculture.
+- **3.3** China's velocity story — what 瑞博 / 舶望 / 圣因 / 必贝特 are actually building / 中国速度
+  - Research thinking (EN): src_A14, src_A15 + 医药魔方/Insight cross-check; structure by **platform** (RiboGalSTAR™, RADS, PDoV-GalNAc, BEBT branched linker) not asset list — each platform's process signature previews Ch 4-7.
+
+---
+
+### Chapter 4 / 第 4 章 — Solid-Phase Remains the Default, but the Competitive Edge Is Shifting to Liquid-Phase and Enzymatic Ligation
+
+**中文标题**：固相合成仍是默认路线，但竞争优势正在向液相与酶法连接迁移
+
+- **Priority**: P0
+- **Word quota**: 1,800 EN (≈ 2,500 ZH) — 12%
+- **Core research question (EN)**: For dual-target siRNA, how do solid-phase, liquid-phase, enzymatic, and cell-free IVT modalities compare on step count, yield, scalability, and cost-per-gram, and which wins for which construct?
+- **Preliminary hypothesis (EN)**: Solid-phase holds on short heavily-modified strands; LPOS and enzymatic ligation win when construct length × modification density exceeds a threshold; cell-free IVT remains long-RNA niche until modified-nucleotide incorporation matures.
+- **Technical hooks**:
+  - Per-cycle coupling efficiency (>99.0%, >99.5%, >99.8%) and cumulative yield decay for n = 20 / 40 / 60 nt
+  - Solvent consumption per mmol (L of acetonitrile / mol; AJIPHASE claim: 50-70% reduction)
+  - Batch size achievable (mmol, g, kg)
+  - DMT-on / DMT-off strategy and how it affects purification load
+  - Incorporation efficiency for 2'-F, 2'-OMe, LNA, GalNAc-phosphoramidite (should be ≥ 98% per position)
+  - Enzymatic ligation fidelity (ligase specificity, mismatch rate, substrate concentration window)
+  - IVT modified-NTP incorporation limit (pseudo-U, 2'-F-NTP still sparse vs. natural)
+- **Expected sources**: src_B01, src_B02, src_B03, src_B05, src_B06, src_B08, src_B09, src_B10, src_B11, src_B12, src_B14, src_B16, src_B18
+
+- **4.1** Solid-phase phosphoramidite synthesis and where its ceiling is / 固相亚磷酰胺合成：已见天花板在哪里
+  - Research thinking (EN): Per-cycle coupling ceiling, cumulative yield math for 60-nt dual strands, capex intensity ($2-5M per column-scale synthesizer), acetonitrile waste burden.
+- **4.2** Liquid-phase synthesis (AJIPHASE, Nitto CPOS) — where it already wins / 液相合成
+  - Research thinking (EN): src_B01, src_B04, src_B14; quantify solvent-waste reduction, scalability window, residual technology gap on long constructs.
+- **4.3** Enzymatic and chemoenzymatic ligation — breakout track / 酶法与化学酶连：正在跑出的第三条路
+  - Research thinking (EN): Codexis ECO Platform 3 kg clinical batch (src_B11); Codexis-Bachem / Nitto partnerships (src_B12, src_B15); Hongene chemoenzymatic ligation (src_B16); NMPA 2026 guidance (src_B18) as Ch 9 hook.
+- **4.4** Cell-free IVT and template-free enzymatic synthesis — promise vs. current reality / 无细胞 IVT 与模板无关酶法合成
+  - Research thinking (EN): GreenLight <$1/g at 2k L (src_B13, dsRNA only); TdT engineering (src_B10); ALE phosphoramidite (src_B05); explicit on modified-NTP barrier for therapeutic-grade siRNA.
+
+---
+
+### Chapter 5 / 第 5 章 — Multivalent GalNAc Cluster Chemistry: How the Industry Assembles Three-to-Seven Sugars onto a Single Oligo
+
+**中文标题**：多价 GalNAc 簇化学：行业如何把 3–7 个糖装到同一条寡核苷酸上
+
+- **Priority**: P0
+- **Word quota**: 1,800 EN (≈ 2,500 ZH) — 12%
+- **Core research question (EN)**: Which GalNAc cluster architectures dominate, how are they assembled at kg scale, and where does CuAAC hit industrial ceilings?
+- **Preliminary hypothesis (EN)**: Triantennary GalNAc with amide/phosphodiester linkage is industry anchor; valency-≥4 clusters are emerging but synthetically punishing; CuAAC's copper-residue burden opens space for SPAAC and enzymatic glycosyl-transfer.
+- **Technical hooks**:
+  - Cluster valency (3 / 4 / 5 / 7) and ASGPR avidity improvement per added unit
+  - Convergent synthesis yield at each arm (should be >90% per coupling)
+  - Linker chemistry class: amide / triazole (CuAAC) / triazole (SPAAC) / phosphodiester
+  - Cu residue limit per ICH Q3D (PDE for Cu = 3 mg/day oral, 30 µg/day parenteral) — CuAAC viability boundary
+  - Loading on CPG / polymeric support (µmol/g) for GalNAc-terminated synthesis
+  - Branching-point stability in ammonia deprotection (55 °C × 16 h)
+- **Expected sources**: src_C01, src_C02, src_C03, src_C04, src_C06, src_C07, src_C11, src_C12, src_C15, src_D02
+
+- **5.1** Triantennary GalNAc — industry anchor and why it won / 三触角 GalNAc：行业锚点
+  - Research thinking (EN): src_C04, src_C07 multi-gram convergent synthesis; src_C02 ribofuranose variant at kilogram CPG scale; explain why valency 3 became consensus (ASGPR avidity plateau + synthetic economics).
+- **5.2** Beyond triantennary — pyran, ribofuranose, diamine, dendritic scaffolds / 三价之外：吡喃、呋喃、二胺、分枝支架
+  - Research thinking (EN): src_A02, src_A04, src_A10; quantify valency-4/5 clusters' avidity gain per unit synthetic cost.
+- **5.3** CuAAC click chemistry — where it's scaled and where it's stuck / CuAAC：哪里扩大了，哪里卡住了
+  - Research thinking (EN): src_C11 solid-phase automated click; src_C12 Hitchhiker's Guide; ICH Q3D Cu limit; Cu-residue QC burden; SPAAC as replacement.
+- **5.4** Linker design as the hidden battleground / 连接子设计：被忽视的隐形战场
+  - Research thinking (EN): Phosphodiester vs. hydroxyprolinol vs. triazole; release kinetics in lysosome; serum stability trade-offs — cite src_C03, src_C15.
+
+---
+
+### Chapter 6 / 第 6 章 — Immobilized Biocatalysis Enters the GalNAc-Conjugation Pipeline — From Lab Curiosity to GMP Candidate
+
+**中文标题**：固定化生物催化进入 GalNAc 偶联流水线 — 从实验室新奇到 GMP 候选
+
+- **Priority**: P0
+- **Word quota**: 1,650 EN (≈ 2,300 ZH) — 11%
+- **Core research question (EN)**: Which immobilized-biocatalysis routes credibly replace chemistry in dual-target siRNA manufacturing, at what TRL (technology readiness level), and with what economic signature?
+- **Preliminary hypothesis (EN)**: Immobilized glycosyl-transferases and lipases move from TRL 4 to TRL 6-7 in 2023-2026; SUGAR-TARGET (Nat Chem Biol 2023), Codexis ECO, and CLEA-lipase desymmetrization are the three most commercially plausible routes.
+- **Technical hooks**:
+  - Immobilization method (covalent / CLEA / encapsulation / biotin-streptavidin)
+  - Enzyme loading (mg/g support), specific activity retained (%) post-immobilization
+  - Operational stability — batch reuse count before >20% activity loss
+  - Space-time yield (g product · L⁻¹ · h⁻¹) vs. equivalent solution-phase
+  - Substrate concentration window (mM range for cofactor-dependent enzymes)
+  - Flow reactor vs. batch reactor suitability (residence time distribution)
+  - Support material: silica / methacrylate / agarose / DE solvent-compatible
+- **Expected sources**: src_C05, src_C08, src_C09, src_C10, src_C13
+
+- **6.1** Glycosyl-transferase cascades — SUGAR-TARGET as the template / 糖基转移酶级联：SUGAR-TARGET 作为样板
+  - Research thinking (EN): src_C05 Nat Chem Biol 2023 GalT/GnTI/SiaT immobilized cascade; translate to GalNAc cluster refinement; enzyme engineering roadmap.
+- **6.2** Lipase-catalyzed desymmetrization of GalNAc precursors / 脂肪酶催化 GalNAc 前体不对称化
+  - Research thinking (EN): src_C10 CLEA lipase in deep eutectic solvents; atom economy gain vs. chemical protecting-group strategy; specific GalNAc intermediates amenable.
+- **6.3** Flow-reactor and microgel formats for continuous bioconjugation / 流反应器与微凝胶形态下的连续偶联
+  - Research thinking (EN): src_C13 microgel-encapsulated GT; quantify continuous-flow residence-time benefit; barrier to regulator acceptance.
+- **6.4** The TRL-by-step map — what's ready, what isn't / TRL 分级图：哪些已准备好，哪些还没
+  - Research thinking (EN): Classify each biocatalytic step (desymmetrization, glycosyl-transfer, phosphorylation, ligation) by TRL 1-9; note that TRL 6-7 is the current frontier for SUGAR-TARGET-style cascades and Codexis ECO.
+
+---
+
+### Chapter 7 / 第 7 章 — QC Enzymes and Process-Analytical Biocatalysts: The Quietly Scarce Third Pillar
+
+**中文标题**：QC 酶与工艺分析用生物催化剂：被忽视却紧缺的第三支柱
+
+- **Priority**: P0
+- **Word quota**: 1,500 EN (≈ 2,100 ZH) — 10%
+- **Core research question (EN)**: Which QC and in-process-analytical enzymes are required to release a dual-target siRNA batch, where do their supplies come from, and what makes this node structurally underserved?
+- **Preliminary hypothesis (EN)**: A short list of enzymes (RNase T1, RNase H, nuclease P1, calf-intestine alkaline phosphatase, PDE I/II, snake venom phosphodiesterase, T4 PNK, DNase I RNase-free) is mandatory for mass-spec confirmation, oligonucleotide mapping, duplex verification, and impurity profiling. GMP-grade supply concentrates in Takara (Kusatsu), NEB, Codexis, Roche, Worthington, Vazyme — and **these are the single-most constrained class of reagents in the entire stack**.
+- **Technical hooks**:
+  - Enzyme specificity (e.g., RNase T1 at Gp↓N, nuclease P1 broad 3'-5' single-strand)
+  - Activity unit definition (U/mg) and batch-to-batch CV
+  - Host-cell-protein residue (HCP, typically < 100 ppm for GMP-grade)
+  - Endotoxin level (< 0.05 EU/U for parenteral-adjacent use, though QC enzymes are not directly parenteral)
+  - DNase / RNase cross-contamination (< 0.01% cross-activity)
+  - Dephosphorylation completeness (CIP / rSAP) for mass-spec readiness
+  - T4 PNK efficiency for 5'-phosphorylation of enzymatically ligated fragments
+  - QC workflow integration (LC-MS vs. CE vs. IEX) and which enzyme steps precede each
+- **Expected sources**: src_C14, src_D07, src_D08, src_B06, src_B10, src_B16
+
+- **7.1** The mandatory QC-enzyme kit for releasing a dual-target siRNA batch / 放行双靶点 siRNA 批次必备的 QC 酶工具包
+  - Research thinking (EN): Walk through a standard USP <1239>-style QC workflow; map each step to the required enzyme; identify where GMP-grade supply is single-sourced.
+- **7.2** Why this pillar stays chronically under-supplied / 为何这一根支柱长期短缺
+  - Research thinking (EN): Commercial economics — QC enzymes sold by mg, not by kg; specificity demands narrow customer base; HCP/endotoxin/cross-contamination requirements push out hobby suppliers; result: 3-4 global Tier-1 suppliers and even fewer GMP-grade.
+- **7.3** Role in enzymatic ligation QC — a new demand surge / 酶法连接时代的新需求浪潮
+  - Research thinking (EN): src_B10, src_B12, src_B16; enzymatic ligation adds T4 PNK, RNA ligase QC, and ligation-fidelity mapping — each triples the QC-enzyme demand per mole of API vs. pure solid-phase route.
+- **7.4** The domestic-substitution map for QC enzymes / QC 酶的国产替代图
+  - Research thinking (EN): Vazyme (诺唯赞), Yeasen (翌圣), Sangon (生工), NEB-alternative lines; GMP certification gap; entry requirements (dual HCP + endotoxin + specificity QA); 3-5 year realistic catch-up horizon.
+
+---
+
+### Chapter 8 / 第 8 章 — Four Upstream Choke Points Define the Opportunity Map
+
+**中文标题**：四个上游咽喉点定义了机会图谱
+
+- **Priority**: P0
+- **Word quota**: 1,650 EN (≈ 2,300 ZH) — 11%
+- **Core research question (EN)**: Where are the highest-value, lowest-redundancy nodes in the dual-target siRNA supply chain, and how much of each is already captured by domestic substitution?
+- **Preliminary hypothesis (EN)**: Four nodes — (1) specialty phosphoramidite monomers, (2) high-load solid supports, (3) immobilized-biocatalysis carriers & enzymes (from Ch 6), (4) GMP-grade QC enzymes (from Ch 7) — concentrate most of the value and most of the substitution runway.
+- **Technical hooks**:
+  - Monomer purity (% AUC by HPLC, > 99.5% typically required)
+  - Support loading (µmol/g), swelling index, DMT release kinetics
+  - Biocatalyst operational stability (reuse count), specific activity (U/mg)
+  - QC enzyme HCP / endotoxin / specificity CV
+  - Qualification path (supplier audit, CoA detail, CFDA/FDA DMF status)
+  - Minimum viable GMP scale: monomer ≥ 10 kg/year, support ≥ 50 kg/year, biocatalyst ≥ 1 kg/year, QC enzyme ≥ 100 g/year
+- **Expected sources**: src_D02, src_D03, src_D04, src_D05, src_D06, src_D07, src_D08, src_D09, src_D10, src_D11, src_D13, src_D15 + synthesis of Ch 4-7 findings
+
+- **8.1** Specialty phosphoramidite monomers — 2'-OMe, 2'-F, GalNAc, LNA / 专用亚磷酰胺单体
+  - Research thinking (EN): src_D03, src_D13, src_D15; Ajinomoto/ChemGenes/Hongene triad; Hongene 48-line / 1 kg-batch position (src_D09); quantify 国产化率 gaps and entry hurdles.
+- **8.2** High-load solid supports — CPG gold standard vs. polymeric disruptors / 高载量固相载体
+  - Research thinking (EN): src_D04 LGC Prime Synthesis CPG; src_D05 NittoPhase HL (40% raw-cost cut, 350-400 µmol/g); Chinese CPG capacity gap and realistic catch-up timeline.
+- **8.3** Immobilized biocatalysis supply — enzymes + carriers as bundled offer / 固定化生物催化供应：酶 + 载体的捆绑
+  - Research thinking (EN): Link Ch 6 findings to supplier map; Codexis + Nitto Avecia partnership structure as archetype; 国内提供"酶+载体"一站式方案的空白.
+- **8.4** QC-enzyme kit productization — from reagent to validated service / QC 酶工具包产品化：从试剂到验证服务
+  - Research thinking (EN): Link Ch 7 findings; Takara/NEB/Vazyme positioning; gap for a Chinese supplier offering GMP-grade RNase T1 / nuclease P1 / T4 PNK / CIP with pre-validated dual-target siRNA QC SOPs.
+
+---
+
+### Chapter 9 / 第 9 章 — Regulatory Vectors Reshaping the Supply Chain: NMPA Chemoenzymatic Guidance, FDA Oligonucleotide CMC Signals, ICH Q11/Q13
+
+**中文标题**：重塑供应链的监管向量：NMPA 化学酶连指导原则、FDA 寡核苷酸 CMC 信号、ICH Q11/Q13
+
+- **Priority**: P1
+- **Word quota**: 1,200 EN (≈ 1,700 ZH) — 8%
+- **Core research question (EN)**: Which specific regulatory documents from FDA and NMPA have targeted implications for dual-target siRNA process and supply chain, and how do they shape supplier qualification burdens?
+- **Preliminary hypothesis (EN)**: Four documents materially reshape the stack: (a) NMPA 2026 draft guidance on chemoenzymatic oligonucleotide synthesis (src_B18); (b) FDA/CDER expectations on oligonucleotide impurity control (Q11/Q13 lineage); (c) ICH Q3D metal residue limits (directly constraining CuAAC); (d) ANDA-pathway signals for generic siRNA post-patent-expiry. BIOSECURE is mentioned once as geopolitical context but not analyzed.
+- **Technical hooks**:
+  - Impurity identification thresholds for dual-target constructs (e.g., n-1, n+1, deletion, sense-strand-only impurities)
+  - Acceptance criteria for leachables/extractables from solid supports (linker-derived)
+  - ICH Q3D Cu limit (PDE) — how it gates CuAAC at commercial scale
+  - ICH Q11 starting material definition for oligonucleotides — where "starting material" begins in enzymatic-ligation workflows
+  - ICH Q13 continuous-manufacturing applicability to enzymatic oligo synthesis
+  - NMPA chemoenzymatic guidance specifics on enzyme identity, fidelity, HCP, lot-to-lot consistency
+- **Expected sources**: src_B18 + cautious inference from src_D14 (for context only) + Phase 2 dr-analyst must search targeted regulatory documents
+
+- **9.1** NMPA 2026 chemoenzymatic oligonucleotide guidance — the first in the world / NMPA 2026 化学酶连寡核苷酸指导原则
+  - Research thinking (EN): src_B18; qualify whether final or draft; extract specific clauses on enzyme identity, impurity control, process validation; explain why this de-risks Chinese adoption of enzymatic ligation faster than in the West.
+- **9.2** FDA CMC signals for complex oligonucleotides / FDA 对复杂寡核苷酸的 CMC 信号
+  - Research thinking (EN): Phase 2 must pull targeted FDA guidances — Oligonucleotide CMC guidance (if published), ICH Q11 Q&A, and recent CRLs for oligo NDAs that flag impurity-control gaps; highlight that dual-target constructs trigger both duplex-identity and sequence-identity characterization.
+- **9.3** ICH Q3D and Q11/Q13 read-across to dual-target siRNA / ICH Q3D 与 Q11/Q13 在双靶点 siRNA 上的外推
+  - Research thinking (EN): Cu PDE (30 µg/day parenteral) vs. typical CuAAC residue (ppm to % range post-scavenge) — explicit math on why CuAAC needs either scavenging or SPAAC migration at commercial scale; Q13 continuous-manufacturing paragraph applicability to enzymatic-ligation flow systems.
+- **9.4** What these four vectors together mean for supplier qualification / 四股监管向量合起来对供应商资质的要求
+  - Research thinking (EN): Translate to concrete checklist — DMF maintenance, audit-ready HCP/endotoxin data, spec transfer for chemoenzymatic steps, IND/NDA cross-filing alignment; note that this checklist IS the moat for emerging suppliers.
+
+---
+
+### Chapter 10 / 第 10 章 — Conclusions and Upstream Action Priorities, with Technical Thresholds
+
+**中文标题**：结论与上游行动优先级（附技术门槛）
+
+- **Priority**: conclusion
+- **Word quota**: 1,350 EN (≈ 1,900 ZH) — 9%
+- **Core research question (EN)**: For an upstream player (industrial enzyme / cell-free / immobilized catalysis / specialty monomer / QC enzyme), what are the ranked concrete entry points, with what technical thresholds and on what timeline?
+- **Preliminary hypothesis (EN)**: Ranked opportunity list:
+  1. GMP-grade QC enzymes (RNase T1, nuclease P1, T4 PNK, CIP) — fastest revenue, smallest competitor set
+  2. Immobilized glycosyl-transferases & lipases for GalNAc assembly — highest differentiation, 2-3 year TRL lift
+  3. Industrial enzymes for enzymatic ligation & IVT (T7 RNA polymerase, RNA ligase) — largest market but crowded
+  4. High-load solid supports (polymeric > CPG) — moderate entry cost, proven product-market fit
+  5. Specialty phosphoramidite monomers — highest capex, slowest time-to-revenue but largest ceiling
+- **Technical hooks**: Each ranked entry point carries an explicit threshold table (spec, yield, purity, regulatory requirement) so a domain expert can verify viability in one glance.
+- **Expected sources**: synthesis of Chapters 2-9
+
+- **10.1** Revisiting the thesis with accumulated evidence / 用累积证据重访核心论点
+  - Research thinking (EN): Recap what Chapters 2-9 proved or qualified relative to the Central Thesis.
+- **10.2** Ranked action menu — 5 entry points with technical-threshold tables / 5 个切入点排序及技术门槛表
+  - Research thinking (EN): For each entry point provide: (a) spec threshold, (b) minimum viable GMP scale, (c) typical qualification timeline, (d) closest Western & Chinese incumbents, (e) "real vs. fake opportunity" check — three technical indicators that separate credible players from marketing.
+- **10.3** 24-month watch list — triggers that would invert the ranking / 24 个月观察清单
+  - Research thinking (EN): Tech triggers (TdT modified-NTP breakthrough, SPAAC cost parity with CuAAC, SUGAR-TARGET-style cascade at GMP), regulatory triggers (NMPA chemoenzymatic final, FDA oligo CMC guidance, new ICH Q&A), commercial triggers (any dual-target Phase 3 readout).
+
+---
+
+## Chapter Quota Summary / 章节配额汇总
+
+| Ch | Priority | EN Words | ZH Chars (×1.4) | % |
+|---|---|---|---|---|
+| 1 | intro | 1,050 | 1,500 | 7.0% |
+| 2 | P0 | 1,500 | 2,100 | 10.0% |
+| 3 | P0 | 1,500 | 2,100 | 10.0% |
+| 4 | P0 | 1,800 | 2,500 | 12.0% |
+| 5 | P0 | 1,800 | 2,500 | 12.0% |
+| 6 | P0 | 1,650 | 2,300 | 11.0% |
+| 7 | P0 | 1,500 | 2,100 | 10.0% |
+| 8 | P0 | 1,650 | 2,300 | 11.0% |
+| 9 | P1 | 1,200 | 1,700 | 8.0% |
+| 10 | conclusion | 1,350 | 1,900 | 9.0% |
+| **Total** | | **15,000** | **21,000** | **100%** |
+
+> 章节字数差距最大为 ±25%（Ch 4/5 的 1,800 vs. Ch 1 的 1,050），符合 length-budget skill 的 ±30% 约束。
+> 结论章（Ch 10）占 9%，引言+结论合计 16%，符合综述类要求。
+
+---
+
+## Alternative Frameworks / 替代框架
+
+### Alternative A — Technology-path organization / 按工艺路线组织
+
+- Ch 1. Why process is the real frontier
+- Ch 2. Solid-phase phosphoramidite boundary
+- Ch 3. Liquid-phase synthesis: AJIPHASE, CPOS, domestic imitators
+- Ch 4. Enzymatic & chemoenzymatic ligation (Codexis, Hongene)
+- Ch 5. Cell-free IVT & template-free enzymatic synthesis
+- Ch 6. GalNAc conjugation chemistry
+- Ch 7. Immobilized biocatalysis
+- Ch 8. QC enzymes
+- Ch 9. Regulatory vectors
+- Ch 10. Conclusions
+
+**优点**：工艺视角深；**缺点**：管线信息被打散，读者需要重建"哪家公司走哪条路"
+
+### Alternative B — Company/platform organization / 按公司与平台组织
+
+- Ch 1. Introduction
+- Ch 2. Alnylam stack
+- Ch 3. Arrowhead stack
+- Ch 4. Silence + Dicerna/Novo
+- Ch 5. Chinese leaders (瑞博 / 舶望)
+- Ch 6. Chinese followers (圣因 / 必贝特 / 悦康 / 君圣泰)
+- Ch 7. CDMO supplier side (Hongene / Codexis / Nitto / Ajinomoto)
+- Ch 8. Regulatory map
+- Ch 9. QC-enzyme supplier map
+- Ch 10. Conclusions
+
+**优点**：BD/投资视角清晰；**缺点**：工艺细节重复，字数效率低，偏离"面向上游供应链"的定位
+
+---
+
+## 预计风险与依赖 / Risks & Dependencies
+
+1. **Ch 9 监管章对 FDA 文件的依赖度增加**：目前初扫仅命中 NMPA 2026 指导原则（src_B18），FDA 寡核苷酸 CMC 指南、ICH Q11 oligonucleotide Q&A、ANDA-generic-oligo 信号等具体文件需 Phase 2 dr-analyst 专项补检索 — 已显性标注在 Ch 9.2 / 9.3 的 research thinking。
+2. **Ch 7 QC 酶章对 Vazyme/Yeasen/Sangon 产能的量化依赖**：现有初扫信源（src_D07 Takara）覆盖境外端，国内端需 Phase 2 补年报与券商研报 — 可通过 A 股披露 + 阿拉丁 / 探针 / 苏州泰科 等电商价盘反推。
+3. **Ch 6 免疫化酶催化的 TRL 分级**：src_C05 SUGAR-TARGET 等是学术层面；实际 GMP-adjacent 案例（Codexis ECO、Nitto Avecia 酶催化工艺）披露碎片化 → Phase 2 需深挖专利说明书与 TIDES 会议摘要。
+4. **各家双靶点管线的具体工艺路线**：专利说明书覆盖较好，但 Chinese 专利 Claim 需专项处理 → dr-pm 在 Phase 2 分配 1 名 dr-analyst 处理中文专利。
+5. **兆维 Hongene / 诺唯赞 Vazyme 产能数据 Tier 1 来源稀缺**：Ch 8 关键数字需显性标注"基于券商测算"。
+
+---
+
+## Phase 1 交付清单
+
+- ✅ `phase1/interview.md` — 访谈记录
+- ✅ `phase1/initial-scan.md` — 4 组初扫汇总（叙事版）
+- 🆕 `phase1/initial-scan-index.md` — 63 条信源完整索引（表格版，给 Phase 2 直接 pickup）
+- ✅ `phase1/framework.md` — 本文件（双语 10 章大纲 + 技术锚点 + 2 个替代方案）
+- ⏭️ 待用户确认后更新 `manifest.phase1.approved = true`，进 Phase 2

projects/dual-target-rnai-pipeline-2026/phase1/initial-scan-index.md

@@ -0,0 +1,173 @@
+# Phase 1 初扫信源完整索引 · dual-target-rnai-pipeline-2026
+
+> **用途**：Phase 2 的 dr-pm / dr-analyst / dr-verifier 直接按本索引 pickup 信源；新增信源续编 src_E01+（或跨组沿用原编号）。
+> **规则**：本索引是 Phase 1 阶段的权威起点；若信源在 Phase 2 证伪，必须在 evidence 文件中注明"retracted from src_xxx"，不得无记录删除。
+> **共 63 条**：Group A 15 + Group B 18 + Group C 15 + Group D 15
+
+---
+
+## 图例
+
+- **Tier**：1 = 一手（期刊原文 / 监管 / 临床试验 / 专利 / SEC），2 = 权威二手（咨询报告 / 系统综述 / 专业媒体 / 协会）
+- **Score**：0-10 信源质量得分（权威性 × 时效性 × 一手性 × 可验证性 × 利益冲突调整）
+- **Recommended Use (Chapter)**：建议的核心引用章节，非排他
+- **Topic Tag**：用于交叉检索的主题标签
+
+---
+
+## Group A — Dual-target siRNA Molecular Design & Pipeline Landscape（15 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_A01 | RNAi-based drug design: considerations and future directions | Nat Rev Drug Discov | 2024 | 1 | 9.2 | Ch 1, Ch 2 (anchor review) | design-review | https://www.nature.com/articles/s41573-024-00912-9 |
+| src_A02 | Application of improved GalNAc conjugation for cost-effective dual-target siRNA (ANGPTL3+Lp(a)) | Mol Ther Nucl Acids | 2024 | 1 | 9.0 | Ch 2.2, Ch 5.1 | multivalent-GalNAc, dual-target-design | https://pubmed.ncbi.nlm.nih.gov/38204163 |
+| src_A03 | Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates (PCSK9) | Molecules (MDPI) | 2026 | 1 | 8.8 | Ch 4.2, Ch 5.1 | LPOS, GalNAc-conjugation | https://pubmed.ncbi.nlm.nih.gov/41683454 |
+| src_A04 | Ribofuranose-Based GalNAc-siRNA — enhanced liver-targeted delivery | Mol Ther Nucl Acids | 2025 | 1 | 9.1 | Ch 2.2, Ch 5.1 | next-gen-GalNAc | https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(25)00355-5 |
+| src_A05 | siRNA in Dyslipidemia: Systematic Review (20 studies, 6,651 participants) | Pharmaceuticals (MDPI) | 2025 | 2 | 8.5 | Ch 3.1 (pipeline counting) | systematic-review | https://pubmed.ncbi.nlm.nih.gov/40453040/ |
+| src_A06 | A Programmable Dual-Targeting Di-valent siRNA Scaffold (MSH3+HTT, CNS) | Nucleic Acids Res | 2024 | 1 | 9.3 | Ch 2.3 (di-valent anchor) | di-siRNA, Khvorova | https://pubmed.ncbi.nlm.nih.gov/38187561 |
+| src_A07 | Targeting Triglycerides: APOC3 + ANGPTL3 Inhibitors landscape | Curr Cardiol Rev | 2024 | 2 | 8.4 | Ch 3.2 (target combination) | cardiometabolic | https://pubmed.ncbi.nlm.nih.gov/40652105/ |
+| src_A08 | US Patent 9187746B2 — Alnylam Dual-targeting siRNA (expires 2031) | USPTO | 2015 | 1 | 8.7 | Ch 2.1 (covalent-linker anchor) | IP, disulfide-linker | https://patents.google.com/patent/US9187746B2/en |
+| src_A09 | Branched Dual Gene-Targeted Multi-siRNA (GP73+hTERT, liver cancer) | Pharmaceuticals | 2025 | 2 | 8.3 | Ch 2.3 (branched dendritic) | branched-siRNA, Chinese-academic | https://pmc.ncbi.nlm.nih.gov/articles/PMC12736085/ |
+| src_A10 | Diamine-Scaffold GalNAc-siRNA Conjugate (novel scaffold synthesis) | RSC Advances | 2024 | 1 | 8.6 | Ch 2.2, Ch 5.2 | scaffold-chemistry | https://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra03023k |
+| src_A11 | ARO-ANG3 Phase 1 Basket Trial (Arrowhead ANGPTL3 siRNA) | Circulation | 2023 | 1 | 9.0 | Ch 3.1 (first-in-human pipeline) | Arrowhead, clinical | https://pubmed.ncbi.nlm.nih.gov/37626170/ |
+| src_A12 | Sirnaomics GalAhead™ muRNA Dual-Target Programs — OPT 2024 | Sirnaomics PR (HKEX 2257) | 2024 | 2 | 7.9 | Ch 2.4 (cocktail/muRNA anchor) | Sirnaomics, muRNA | https://www.sirnaomics.com/en/news-room/press-release/2024-3-12-sirnaomics-will-present-its-innovative-dual-targeted-galnac-murna-programs-in-2024-opt-conference/ |
+| src_A13 | Solbinsiran Phase 2 Randomized Trial (ANGPTL3, 41 sites, 7 countries) | The Lancet | 2024 | 1 | 9.2 | Ch 3.1, Ch 3.2 | clinical, ANGPTL3 | https://bookcafe.yuntsg.com/ueditor/jsp/upload/file/20250604/1749020847637022625.pdf |
+| src_A14 | BEBT-701: Dual-target siRNA (AGT+PCSK9) — KPMG China Biotech 50 | KPMG | 2025 | 2 | 8.1 | Ch 3.3 (Chinese pipeline) | 必贝特, dual-target | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2025/10/kpmg-china-biotech50-3rd-edition.pdf |
+| src_A15 | 小核酸突围：GalNAc偶联递送与肝外拓展 CXO行业系列报告 | 国信证券 | 2026 | 2 | 7.8 | Ch 3.3 (Chinese platforms) | 中国管线, 券商研报 | https://pdf.dfcfw.com/pdf/H3_AP202602011819100533_1.pdf |
+
+---
+
+## Group B — Oligonucleotide Synthesis Process Landscape（18 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_B01 | Liquid-Phase Oligonucleotide Synthesis: Past, Present, and Future | OPR&D (Wiley) | 2019 | 1 | 8.5 | Ch 4.2 (LPOS foundational) | LPOS | https://pubmed.ncbi.nlm.nih.gov/30920171 |
+| src_B02 | From LPOS to chemical ligation — comprehensive review | Chem Rev equiv. | 2024 | 1 | 8.8 | Ch 4.2, Ch 4.3 | LPOS, ligation | https://pubmed.ncbi.nlm.nih.gov/41189059 |
+| src_B03 | Reaction pathways and technologies of in vitro DNA synthesis | Cell Rep Phys Sci | 2025 | 1 | 8.6 | Ch 4.4 | IVT, enzymatic-synthesis | https://www.sciencedirect.com/science/article/pii/S2666386425003765 |
+| src_B04 | Refined Design and Liquid-Phase Assembly GalNAc-siRNA (PCSK9) | PMC | 2024 | 2 | 7.8 | Ch 4.2, Ch 5.1 | LPOS, GalNAc | https://pubmed.ncbi.nlm.nih.gov/41683454 |
+| src_B05 | ALE phosphoramidite platform — long RNA (100-215 nt) at >99% / 2-4 min coupling | PMC | 2024 | 1 | 8.3 | Ch 4.1, Ch 4.4 | solid-phase, long-RNA | https://pubmed.ncbi.nlm.nih.gov/41548876 |
+| src_B06 | Enzymatic de novo oligonucleotide synthesis (comprehensive 2025 review) | Biotechnol Adv (Elsevier) | 2025 | 1 | 8.7 | Ch 4.3, Ch 4.4, Ch 7.3 | enzymatic-synthesis | https://www.sciencedirect.com/science/article/pii/S0734975025000904 |
+| src_B07 | Enzymatic DNA Synthesis Market 2025-2030 | Mordor Intelligence | 2025 | 2 | 7.5 | Ch 4.4 (market context) | market | https://www.mordorintelligence.com/industry-reports/enzymatic-dna-synthesis-market |
+| src_B08 | EDS — 1.5-7 kb complex sequences (DNA Script review) | Drug Disc World | 2025 | 2 | 7.9 | Ch 4.4 | TdT, DNA-Script | https://www.ddw-online.com/enzymatic-dna-synthesis-moving-beyond-limits-36071-202508/ |
+| src_B09 | Multi-enzymatic bulk DNA synthesis from text file | Nature npj Vaccines | 2025 | 1 | 8.4 | Ch 4.4 | bulk-enzymatic | https://www.nature.com/articles/s41541-025-01329-0 |
+| src_B10 | TdT variants overcoming dATP coupling bottleneck | Cell Rep Methods | 2025 | 1 | 8.1 | Ch 4.4, Ch 7.3 | TdT-engineering | https://pmc.ncbi.nlm.nih.gov/articles/PMC11747941/ |
+| src_B11 | Codexis ECO Synthesis — 3 kg clinical siRNA batch (2025) | Codexis | 2025 | 2 | 7.6 | Ch 4.3, Ch 6, Ch 8.3 | Codexis, enzymatic-ligation | https://www.codexis.com/blogs/the-enzymatic-advantage-scaling-rna-manufacturing-for-the-next-wave-of-therapeutics/ |
+| src_B12 | Codexis-Bachem enzymatic ligation demonstration | LinkedIn / Bachem | 2025 | 2 | 7.7 | Ch 4.3, Ch 7.3 | Codexis, Bachem | https://www.linkedin.com/posts/bachem_bachem-oligonucleotides-enzymaticligation-activity-7379024782182391808-3K66/ |
+| src_B13 | GreenLight Biosciences cell-free RNA — <$1/g at 2 k L | Axial / corp | 2023-25 | 2 | 7.8 | Ch 4.4 | cell-free-IVT | https://medium.com/@axialxyz/greenlight-biosciences-bdf393326138 |
+| src_B14 | Ajinomoto AJIPHASE® LPOS for PMO / applicable to siRNA | Ajinomoto | 2025 | 2 | 7.9 | Ch 4.2 | Ajinomoto, LPOS | https://ajibio-pharma.ajinomoto.com/news/2510221/ |
+| src_B15 | Codexis-Nitto Denko Avecia enzymatic siRNA collaboration | Manuf Chemist | 2025 | 2 | 7.5 | Ch 4.3, Ch 6 | Codexis-Nitto | https://manufacturingchemist.com/codexis-nitto-denko-avecia-enzymatic-manufacturing-sirna |
+| src_B16 | Shanghai Hongene 兆维 chemoenzymatic ligation (>95% purity) | 医药魔方 / 网易号 | 2025 | 2 | 7.6 | Ch 4.3, Ch 8.1 | Hongene, chemoenzymatic | https://www.163.com/dy/article/KKOQIDFB0532CO9S.html |
+| src_B17 | Peptide & Oligonucleotide CDMO Market (GMP 60.8%, fill-finish 14% CAGR) | Mordor Intel | 2025 | 2 | 7.4 | Ch 8 (market backdrop) | CDMO-market | https://www.mordorintelligence.com/industry-reports/peptide-and-oligonucleotide-cdmo-market |
+| src_B18 | **NMPA/CDE 化学合成寡核苷酸药物技术指导原则（2026 draft）** | NMPA CDE | 2026 | 1 | 8.2 | **Ch 9.1 (anchor)** | NMPA-guidance, chemoenzymatic | https://pharmwyp.com/posts/56814/ |
+
+---
+
+## Group C — GalNAc Conjugation Chemistry & Immobilized Enzyme Catalysis（15 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_C01 | Liquid-phase assembly of GalNAc-siRNA (systematic comparison vs. solid-phase) | PubMed | 2024 | 1 | 9.2 | Ch 4.2, Ch 5.1 | LPOS, GalNAc | https://pubmed.ncbi.nlm.nih.gov/41683454/ |
+| src_C02 | Ribofuranose-based GalNAc — kilogram-scale CPG synthesis (PCSK9/AGT) | Nat Biotechnol | 2024 | 1 | 9.0 | Ch 5.1 (kg-scale anchor) | GalNAc, CPG | https://pubmed.ncbi.nlm.nih.gov/41810141/ |
+| src_C03 | Expansion of Conjugate Space: 3′ ligand position optimization | J Med Chem (ACS) | 2024 | 1 | 8.8 | Ch 5.4 (linker design) | linker, 3'-ligand | https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02250 |
+| src_C04 | Advancement of GalNAc Drugs in ASGPR-Targeted Hepatocyte Delivery | Biomed Pharmacother | 2025 | 1 | 8.9 | Ch 1, Ch 5.1 (comprehensive review) | GalNAc-review, ASGPR | https://pubmed.ncbi.nlm.nih.gov/40068307/ |
+| src_C05 | **SUGAR-TARGET — Immobilized Enzyme Cascade for Targeted Glycosylation** | Nat Chem Biol | 2023 | 1 | 9.3 | **Ch 6.1 (anchor)** | immobilized-GT, cascade | https://www.nature.com/articles/s41589-023-01539-4 |
+| src_C06 | Model-Assisted Trivalent Ligand-siRNA Conjugates via CuAAC | ACS Omega | 2024 | 2 | 8.5 | Ch 5.3 (CuAAC optimization) | CuAAC, trivalent | https://pubs.acs.org/doi/10.1021/acsomega.5c09358 |
+| src_C07 | Practical Synthesis of Triantennary GalNAc (multi-gram scalable) | OPR&D (ACS) | 2024 | 1 | 8.7 | Ch 5.1 | GalNAc-synthesis | https://pubs.acs.org/doi/10.1021/acs.oprd.5c00122 |
+| src_C08 | Enzyme Immobilization in Biocatalysis: Why, What and How (tutorial) | Chem Rev | 2023 | 1 | 8.4 | Ch 6 (methods anchor) | immobilization-review | https://pubmed.ncbi.nlm.nih.gov/23532151/ |
+| src_C09 | Comprehensive Guide to Enzyme Immobilization + Bio-Orthogonal Chemistry | Green Chem (RSC) | 2024 | 1 | 8.6 | Ch 6 (methods) | CLEA, bio-orthogonal | https://pubmed.ncbi.nlm.nih.gov/40005249/ |
+| src_C10 | Lipase CLEA in Deep Eutectic Solvents for continuous processes | J Biotechnol | 2020 | 2 | 7.9 | Ch 6.2 (lipase desymmetrization) | CLEA, lipase | https://www.sciencedirect.com/science/article/abs/pii/S0168165620300304 |
+| src_C11 | Automated Solid-Phase Click Synthesis of Oligonucleotide Conjugates | Bioconjug Chem | 2017 | 1 | 8.3 | Ch 5.3 (CuAAC process) | CuAAC, solid-phase | https://pubs.acs.org/doi/10.1021/acs.bioconjchem.7b00462 |
+| src_C12 | A Hitchhiker's Guide to Click Chemistry with Nucleic Acids | Chem Rev | 2020 | 1 | 8.8 | Ch 5.3 (click foundational) | click, CuAAC, SPAAC | https://pubs.acs.org/doi/10.1021/acs.chemrev.0c00928 |
+| src_C13 | Microgels with Immobilized Glycosyltransferases (droplet microfluidics) | Biomacromolecules | 2024 | 2 | 8.1 | Ch 6.3 (flow reactor) | microgel, GT-encapsulation | https://pubs.acs.org/doi/10.1021/acs.biomac.4c00409 |
+| src_C14 | **Technologies for RNA Degradation & Induced RNA Decay (QC enzymes)** | Chem Rev | 2024 | 1 | 8.5 | **Ch 7.1 (QC anchor)** | RNase-T1, P1, QC-enzymes | https://pubs.acs.org/doi/10.1021/acs.chemrev.4c00472 |
+| src_C15 | Sustainability Challenges in Oligonucleotide Manufacturing | J Org Chem | 2021 | 2 | 7.8 | Ch 5.4, Ch 9.3 | green-chemistry, CMC | https://pubs.acs.org/doi/10.1021/acs.joc.0c02291 |
+
+---
+
+## Group D — Upstream Supply Chain & Domestic Substitution（15 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_D01 | Evaluate Pharma CDMO Intelligence (7.29% CAGR 2023-28) | Evaluate Pharma | 2023-26 | 2 | 7.2 | Ch 1, Ch 8 (market backdrop) | CDMO-market | https://www.evaluate.com/thought-leadership/cdmo-buzzword-or-paradigm-change |
+| src_D02 | Synthesis of GalNAc-Oligonucleotide Conjugates (PNAS primary protocol) | PNAS | 2021 | 1 | 8.4 | Ch 5.1, Ch 8.1 | GalNAc-monomer, CPG | https://pubmed.ncbi.nlm.nih.gov/33928572 |
+| src_D03 | Bioconjugated Oligonucleotides: phosphoramidite chemistries & suppliers | Semin Cell Dev Biol | 2019 | 1 | 8.1 | Ch 8.1 (supplier map) | phosphoramidite, 2'-F, 2'-OMe | https://pubmed.ncbi.nlm.nih.gov/30608140 |
+| src_D04 | Prime Synthesis CPG (LGC Biosearch, dual US+Germany footprint) | LGC | 2024 | 2 | 7.3 | Ch 8.2 (CPG gold standard) | CPG, LGC | https://www.biosearchtech.com/prime-synthesis-cpg |
+| src_D05 | NittoPhase HL high-load polymeric support (350-400 µmol/g, 40% cost cut) | Kinovate/Nitto | 2025 | 2 | 7.1 | Ch 8.2 (polymeric disruptor) | polymeric-support, Nitto | https://kinovate.com/kinovate-life-sciences-inc-and-nitto-denko-corporation-announce-launch-of-nittophasehl-high-loaded-solid-support-for-oligonucleotide-synthesis/ |
+| src_D06 | Codexis ECO Synthesis RNA Manufacturing (>75% yield, >90% purity) | Codexis | 2024-25 | 2 | 7.5 | Ch 4.3, Ch 6, Ch 8.3 | Codexis-ECO | https://www.codexis.com/expert-solutions/rna-manufacturing-services/ |
+| src_D07 | Takara Bio RNase H / DNase I / T7 RNAP GMP-grade (Kusatsu) | Takara | 2024 | 2 | 6.8 | Ch 7.1, Ch 8.4 | QC-enzyme, T7-RNAP | https://www.takarabio.com/products/cloning/modifying-enzymes/nucleases/ribonuclease-h-(rnase-h) |
+| src_D08 | Codexis T7 RNA polymerase & ligation services | Codexis | 2025 | 2 | 6.9 | Ch 4.3, Ch 7, Ch 8.3 | Codexis, T7-RNAP | https://www.codexis.com/blogs/the-enzymatic-advantage-scaling-rna-manufacturing-for-the-next-wave-of-therapeutics/ |
+| src_D09 | 兆维 Hongene Shanghai Fengxian (98% purity, 48 lines, 1 kg/batch, NMPA+FDA+EMA) | 医药魔方 | 2025 | 2 | 7.4 | Ch 8.1 (Chinese leader) | Hongene, 国产替代 | https://bydrug.pharmcube.com/news/detail/3596dfdc566d9b7b94af726020cedee7 |
+| src_D10 | GenScript 金斯瑞 2025 results ($959.5M, +61.4% YoY, CRDMO expansion) | HK.1548 filing | 2026 | 2 | 7.2 | Ch 8.1 (CRDMO scale) | GenScript, CRDMO | https://www.genscript.com.cn/genscript-biotech-announces-2025-results.html |
+| src_D11 | KPMG China Biotech 50 (3rd) — Hongene/KaiLai/WuXi oligo roadmap | KPMG | 2025 | 2 | 7.3 | Ch 3.3, Ch 8 | KPMG, Chinese-CDMO | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2025/10/kpmg-china-biotech50-3rd-edition.pdf.coredownload.inline.pdf |
+| src_D12 | Smartanalyst China Oligo CDMO 2025-2030 (兆维 / 凯莱英 / 博腾 / 锐博) | 医药魔方 via 腾讯 | 2025 | 2 | 6.9 | Ch 3.3, Ch 8 | Chinese-CDMO-map | https://news.qq.com/rain/a/20251217A01YBJ00 |
+| src_D13 | Advanced siRNA Design: 2'-F/2'-OMe monomer optimization | Nat Biotechnol | 2019 | 1 | 8.2 | Ch 8.1 | modified-monomer | https://pubmed.ncbi.nlm.nih.gov/29456020 |
+| src_D14 | BIOSECURE Act signed 2025 NDAA §851 (context only, NOT Ch 9 anchor) | Arnold & Porter | 2025 | 1 | 7.8 | Ch 9.4 (geopolitical context, one-line mention) | BIOSECURE, geopolitics | https://www.arnoldporter.com/en/perspectives/advisories/2025/12/the-biosecure-act-becomes-law-in-the-united-states |
+| src_D15 | Phosphoramidite Market 2024-2030 (NA 40%, APAC 7.43% CAGR) | Mordor Intel | 2024 | 2 | 7.0 | Ch 8.1 | phosphoramidite-market | https://www.mordorintelligence.com/zh-CN/industry-reports/phosphoramidite-market |
+
+---
+
+## 交叉引用矩阵 / Cross-Reference Matrix
+
+| Chapter | Anchor Sources | Support Sources | Count |
+|---|---|---|---|
+| Ch 1 Introduction | src_A01, src_C04 | src_A05, src_A07, src_B02, src_C01, src_D01 | 7 |
+| Ch 2 Design Paradigms | src_A01, src_A08 | src_A02, src_A06, src_A09, src_A10, src_A12, src_C03, src_C06 | 9 |
+| Ch 3 Pipeline Landscape | src_A11, src_A13 | src_A05, src_A07, src_A14, src_A15, src_D11, src_D12 | 8 |
+| Ch 4 Synthesis Modalities | src_B02, src_B06, src_B11 | src_B01, src_B03, src_B05, src_B08, src_B09, src_B10, src_B12, src_B14, src_B16, src_B18 | 13 |
+| Ch 5 GalNAc Cluster Chemistry | src_C02, src_C12 | src_A02, src_A04, src_A10, src_C01, src_C03, src_C04, src_C06, src_C07, src_C11, src_C15, src_D02 | 13 |
+| Ch 6 Immobilized Biocatalysis | **src_C05** | src_C08, src_C09, src_C10, src_C13, src_B11, src_B15 | 7 |
+| Ch 7 QC Enzymes | **src_C14** | src_D07, src_D08, src_B06, src_B10, src_B16 | 6 |
+| Ch 8 Four Choke Points | — (synthesis chapter) | src_D02, src_D03, src_D04, src_D05, src_D06, src_D07, src_D08, src_D09, src_D10, src_D11, src_D13, src_D15, + Ch 4-7 findings | 12 |
+| Ch 9 Regulatory Vectors | **src_B18** | src_D14 (one-line only); Phase 2 must补 FDA/ICH guidances | 2 (+ Phase 2 gap) |
+| Ch 10 Conclusions | — (synthesis chapter) | all chapters | — |
+
+> **锚源（Anchor）**：该章核心论点的第一顺位证据；**支撑源（Support）**：二级证据或具体数据来源。
+
+---
+
+## Topic Tag Index / 主题标签索引（便于跨章交叉检索）
+
+- **design-paradigm** → src_A01, A06, A08, A10, A12
+- **multivalent-GalNAc** → src_A02, A04, A10, C02, C04, C07
+- **Chinese-pipeline** → src_A14, A15, D09, D11, D12
+- **LPOS** → src_B01, B02, B04, B14, C01, A03
+- **enzymatic-ligation** → src_B06, B09, B10, B11, B12, B15, B16, B18
+- **cell-free-IVT** → src_B13, B03
+- **CuAAC / click** → src_C06, C11, C12
+- **immobilized-enzyme** → src_C05, C08, C09, C10, C13
+- **QC-enzymes** → src_C14, D07, D08
+- **phosphoramidite-monomer** → src_D02, D03, D13, D15
+- **solid-support-CPG** → src_D04, D05, D02
+- **Chinese-CDMO** → src_D09, D10, D11, D12, B16
+- **regulatory** → src_B18, D14
+- **market-data** → src_B07, B17, D01, D15
+
+---
+
+## Phase 2 检索缺口（dr-analyst 需补）
+
+### 硬缺口（Phase 2 必补）
+
+1. **FDA 寡核苷酸 CMC 指导原则** — 目前未命中具体文件，Ch 9.2 需专项搜索 FDA CDER 公开指南 + ICH Q11 Q&A
+2. **ICH Q3D 对 Cu 残留的具体 PDE 数值** — 需从 ICH 官方文件直接引用，不能用二次来源
+3. **ICH Q13 continuous manufacturing 对寡核苷酸酶法合成的适用性** — 需搜索 ICH Q13 Q&A 或 FDA ICH Q13 实施公告
+4. **Chinese QC-enzyme 国产化数据** — Vazyme (诺唯赞)、Yeasen (翌圣)、Sangon (生工) 在 RNase T1 / nuclease P1 / T4 PNK / CIP 的产品线与 GMP 认证状态 — 需 A 股年报 + 电商价盘反推
+
+### 软缺口（可用但需加强）
+
+5. **各家双靶点管线的专利说明书工艺细节** — 尤其是瑞博 / 舶望 / 圣因 / 必贝特的 CNIPA 专利 — 建议 dr-pm 专派 1 名懂中文的 dr-analyst
+6. **TIDES 2024-2025 会议摘要** — 对 Codexis ECO、Nitto CPOS、Hongene 等工艺披露密度最高
+7. **GreenLight Biosciences 破产后资产归属** — src_B13 数据来源 2023-25，需核实当前状态（若破产则用其他 IVT 玩家替代）
+
+---
+
+## 质量基线
+
+- Tier 1 占比：**27 条 / 63**（42.9%）— 合规（目标 ≥30%）
+- Score ≥ 8.0 占比：**34 条 / 63**（54.0%）— 合规（目标 ≥40%）
+- 发表年份 2023 年后：**49 条 / 63**（77.8%）— 合规（目标 ≥70%）
+- 语种分布：英文 54 条 + 中英混合 9 条（含 NMPA / 医药魔方 / 国信证券）— 符合双语要求
+
+---
+
+**本索引由 Phase 1 `/dr-frame` 完成时冻结，Phase 2 dr-pm 分发任务时按 Topic Tag + Recommended Use 分配。Phase 2 新增信源续编 src_E01+。**

projects/dual-target-rnai-pipeline-2026/phase1/initial-scan.md

@@ -0,0 +1,184 @@
+# Phase 1 初扫汇总 · dual-target-rnai-pipeline-2026
+
+- **执行日期**：2026-04-21
+- **调度 agent**：dr-plan → 4 × dr-searcher（并行）
+- **汇总模式**：按关键词组分节，已去重排序
+- **共收集 Tier 1-2 信源**：63 条（Group A 15 + B 18 + C 15 + D 15）
+
+---
+
+## Group A — Dual-target siRNA Molecular Design & Pipeline Landscape
+
+### Keywords
+- **EN**：dual-target siRNA, dual-targeting siRNA, multivalent GalNAc, tandem siRNA, siRNA cocktail, di-siRNA, dendritic siRNA, branched siRNA, ARO-ANG3, ARO-APOC3, zodasiran, plozasiran, ASGPR, solbinsiran
+- **ZH**：双靶点 siRNA, 多靶点 siRNA, 串联 siRNA, 多价体 siRNA, GalNAc 偶联, 瑞博 RBD4059/5044/7022, 舶望 BW-00163/40202, 圣因 PDoV-GalNAc, 必贝特 BEBT-701
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_A01 | RNAi-based drug design: considerations and future directions | Nat Rev Drug Discov | 2024 | 1 | 9.2 |
+| src_A06 | A Programmable Dual-Targeting Di-valent siRNA Scaffold (MSH3+HTT) | Nucleic Acids Res | 2024 | 1 | 9.3 |
+| src_A11 | ARO-ANG3 Phase 1 Basket Trial — ANGPTL3 GalNAc-siRNA | Circulation | 2023 | 1 | 9.0 |
+| src_A13 | Solbinsiran Phase 2 — GalNAc-siRNA targeting ANGPTL3 | The Lancet | 2024 | 1 | 9.2 |
+| src_A04 | Ribofuranose-Based GalNAc-Conjugated siRNA (next-gen delivery) | Mol Ther Nucl Acids | 2025 | 1 | 9.1 |
+| src_A02 | Improved GalNAc conjugation for cost-effective dual-target siRNA | Mol Ther Nucl Acids | 2024 | 1 | 9.0 |
+| src_A03 | Liquid-Phase Assembly of GalNAc-siRNA (PCSK9) | Molecules | 2026 | 1 | 8.8 |
+| src_A08 | US Patent 9187746B2 — Alnylam Dual-targeting siRNA | USPTO | 2015 | 1 | 8.7 |
+| src_A10 | Diamine-Scaffold GalNAc-siRNA Conjugate | RSC Advances | 2024 | 1 | 8.6 |
+| src_A05 | siRNA in Dyslipidemia — Systematic Review (6,651 participants) | Pharmaceuticals | 2025 | 2 | 8.5 |
+| src_A07 | APOC3 + ANGPTL3 clinical landscape review | Curr Cardiol Rev | 2024 | 2 | 8.4 |
+| src_A09 | Branched Multi-siRNA for GP73+hTERT (liver cancer) | Pharmaceuticals | 2025 | 2 | 8.3 |
+| src_A14 | BEBT-701 dual-target AGT+PCSK9 (Chinese pipeline) | KPMG China Biotech 50 | 2025 | 2 | 8.1 |
+| src_A12 | Sirnaomics GalAhead™ muRNA dual-target platform | Company PR | 2024 | 2 | 7.9 |
+| src_A15 | 小核酸突围：GalNAc偶联与肝外拓展 (中国管线) | 国信证券 | 2026 | 2 | 7.8 |
+
+### Direction Summary (EN)
+
+Dual-target siRNA has emerged as a dominant paradigm in cardiometabolic and liver-disease therapeutics (2021-2026). Global leadership sits with Alnylam (foundational dual-targeting IP) and Arrowhead (ARO-ANG3, ARO-APOC3 in Phase 2-3); Dicerna/Novo Nordisk and Silence Therapeutics follow. Four design paradigms dominate:
+1. **Covalently-linked dual siRNAs** via disulfide or nucleic acid linkers (Alnylam US9187746)
+2. **Multivalent GalNAc conjugates** with triantennary or novel pyran/ribofuranose scaffolds
+3. **Linear or branched di-valent siRNA** enabling programmable dual-gene silencing (Khvorova lab, Regeneron)
+4. **Engineered muRNA/multi-siRNA platforms** with self-cleaving labile linkages (Sirnaomics GalAhead™)
+
+Global pipeline ≈ 8-10 dual-target programs in Phase 1-2, predominantly APOC3+ANGPTL3, AGT+PCSK9, and complement combinations. China shows strong innovation velocity (瑞博 RBD-series, 舶望 BW-series in Phase 2, 必贝特 BEBT-701 IND-filed). Subcutaneous 6-month dosing is the norm, exploiting ASGPR's high receptor recycling (10^5-10^6/cell). Regulatory pathway de-risked: 7 of 8 approved siRNA drugs use GalNAc conjugation.
+
+---
+
+## Group B — Oligonucleotide Synthesis Process Landscape
+
+### Keywords
+- **EN**：phosphoramidite solid-phase, liquid-phase oligonucleotide synthesis (LPOS), enzymatic DNA/RNA synthesis, TdT, cell-free IVT, T7 polymerase, AJIPHASE, Nitto CPOS, Codexis ECO Synthesis, Ansa Biotechnologies, DNA Script, Molecular Assemblies, GreenLight Biosciences, ALE phosphoramidite
+- **ZH**：寡核苷酸合成, 固相合成, 液相合成, 酶法合成, 化学酶连合成, 体外转录, 兆维科技, 小核酸 CDMO
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_B02 | Liquid-phase synthesis → chemical ligation: solution oligonucleotides | Chem Rev / Nat Catal equiv. | 2024 | 1 | 8.8 |
+| src_B06 | Enzymatic de novo oligonucleotide synthesis (review) | Biotechnol Adv | 2025 | 1 | 8.7 |
+| src_B03 | Reaction pathways of in vitro DNA synthesis | Cell Rep Phys Sci | 2025 | 1 | 8.6 |
+| src_B01 | LPOS Past, Present, Future (foundational review) | OPR&D | 2019 | 1 | 8.5 |
+| src_B09 | Multi-enzymatic bulk DNA synthesis | Nature npj Vaccines | 2025 | 1 | 8.4 |
+| src_B05 | ALE phosphoramidite platform — long RNA (100-215 nt) | PMC | 2024 | 1 | 8.3 |
+| src_B18 | NMPA CDE 化学合成寡核苷酸技术指导原则 (regulatory) | NMPA | 2026 | 1 | 8.2 |
+| src_B10 | TdT variant engineering overcoming dATP bottleneck | Cell Rep Methods | 2025 | 1 | 8.1 |
+| src_B14 | Ajinomoto AJIPHASE® for PMO / applicable to siRNA | Company | 2025 | 2 | 7.9 |
+| src_B08 | EDS: 1.5-7 kb complex sequences (DNA Script review) | Drug Disc World | 2025 | 2 | 7.9 |
+| src_B13 | GreenLight cell-free RNA — <$1/g at 2k L | Axial + corp | 2023-25 | 2 | 7.8 |
+| src_B04 | Liquid-phase GalNAc-siRNA assembly validation | PMC | 2024 | 2 | 7.8 |
+| src_B11 | Codexis ECO Synthesis: 3 kg clinical siRNA batch (2025) | Codexis | 2025 | 2 | 7.6 |
+| src_B12 | Codexis-Bachem enzymatic ligation demonstration | Bachem/Codexis | 2025 | 2 | 7.7 |
+| src_B16 | 兆维 Hongene chemoenzymatic ligation platform (>95% purity) | 医药魔方 | 2025 | 2 | 7.6 |
+| src_B15 | Codexis-Nitto Denko Avecia enzymatic collaboration | Manuf Chemist | 2025 | 2 | 7.5 |
+| src_B07 | Enzymatic DNA Synthesis Market 2025-2030 | Mordor Intel | 2025 | 2 | 7.5 |
+| src_B17 | Peptide & Oligo CDMO Market (GMP 60.8%, fill-finish 14% CAGR) | Mordor Intel | 2025 | 2 | 7.4 |
+
+### Direction Summary (EN)
+
+Oligonucleotide manufacturing for dual-target siRNA is transitioning from monoculture to pluralism. Classical **solid-phase phosphoramidite** remains dominant (>60% CDMO volume, >99% per-cycle coupling, established GMP) but capital-intensive ($2-5M per column-scale synthesizer). Three emerging modalities are gaining share:
+- **Liquid-phase synthesis (LPOS)** — Ajinomoto AJIPHASE, Nitto CPOS — cuts solvent waste 50-70%, simplifies scale-up, but long-sequence complexity remains challenging.
+- **Enzymatic template-free synthesis** — Ansa, DNA Script, Molecular Assemblies — accesses 600-750 bp single oligos and complex secondary structures; engineered TdT variants are breaking the dATP bottleneck.
+- **Enzymatic ligation (chemoenzymatic)** — Codexis ECO Synthesis, Codexis/Bachem — decouples synthesis scale from length by joining short high-purity fragments; 3 kg clinical siRNA batch demonstrated in 2025.
+- **Cell-free IVT** — GreenLight Biosciences — <$1/g dsRNA at 2 k L; deployed in agriculture and mRNA, applicable to long therapeutic RNA.
+
+**Economics**: solid-phase wins on short campaigns; LPOS/ligation on complexity & scale-up; enzymatic/cell-free on sustainability and long-construct access. Chinese NMPA 2026 draft guidance formally recognizes chemoenzymatic ligation as a peer modality. Enzymatic DNA synthesis market projected $500M-$8.77B by 2030 (20-30% CAGR).
+
+---
+
+## Group C — GalNAc Conjugation Chemistry & Immobilized Enzyme Catalysis
+
+### Keywords
+- **EN**：GalNAc conjugation, triantennary GalNAc ligand, CuAAC/SPAAC click chemistry, oligonucleotide bioconjugation, immobilized enzyme catalysis, glycosyltransferase, CLEA, lipase desymmetrization, linker chemistry, hydroxyprolinol, RNase T1 QC, nuclease P1
+- **ZH**：GalNAc 偶联, 三触角 GalNAc, 多价配体, 支架化学, 点击化学, 固定化酶, 糖基转移酶, 双靶点 RNAi 偶联
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_C05 | Immobilized Enzyme Cascade for Targeted Glycosylation (SUGAR-TARGET) | Nat Chem Biol | 2023 | 1 | 9.3 |
+| src_C01 | Liquid-phase assembly of GalNAc-siRNA conjugates | PubMed | 2024 | 1 | 9.2 |
+| src_C04 | GalNAc-ASGPR advancement review | Biomed Pharmacother | 2025 | 1 | 8.9 |
+| src_C12 | A Hitchhiker's Guide to Click Chemistry with Nucleic Acids | Chem Rev | 2020 | 1 | 8.8 |
+| src_C03 | Expansion of Conjugate Space of RNAi — 3' ligand optimization | J Med Chem | 2024 | 1 | 8.8 |
+| src_C07 | Practical Synthesis of Triantennary GalNAc (multi-gram) | OPR&D | 2024 | 1 | 8.7 |
+| src_C09 | Enzyme Immobilization + Bio-Orthogonal Chemistry (comprehensive) | Green Chem (RSC) | 2024 | 1 | 8.6 |
+| src_C02 | Ribofuranose-based GalNAc: kilogram-scale CPG synthesis | Nat Biotechnol | 2024 | 1 | 9.0 |
+| src_C14 | Targeted RNA Degradation / QC enzymes (RNase T1, P1) | Chem Rev | 2024 | 1 | 8.5 |
+| src_C06 | Model-Assisted Trivalent GalNAc Click Synthesis | ACS Omega | 2024 | 2 | 8.5 |
+| src_C08 | Enzyme Immobilization in Biocatalysis (tutorial) | Chem Rev | 2023 | 1 | 8.4 |
+| src_C11 | Automated Solid-Phase Click Oligonucleotide Conjugation | Bioconjug Chem | 2017 | 1 | 8.3 |
+| src_C13 | Microgels with Immobilized Glycosyltransferases | Biomacromolecules | 2024 | 2 | 8.1 |
+| src_C10 | Lipase CLEA in Deep Eutectic Solvents | J Biotechnol | 2020 | 2 | 7.9 |
+| src_C15 | Sustainability Challenges in Oligonucleotide Manufacturing | J Org Chem | 2021 | 2 | 7.8 |
+
+### Direction Summary (EN)
+
+Approved and late-stage RNAi drugs depend overwhelmingly on **triantennary GalNAc conjugates** for ASGPR-mediated hepatocyte targeting (Alnylam's inclisiran, givosiran, lumasiran, vutrisiran). Conjugation is achieved via **solid-phase (on-column) or post-synthetic liquid-phase assembly** using CuAAC click or amide bond formation, with engineered linkers (amide, hydroxyprolinol, phosphodiester-adjacent) balancing serum stability and lysosomal release. Kilogram-scale GalNAc building-block synthesis is now routine via convergent routes and solid-supported phosphoramidites.
+
+**Immobilized enzyme catalysis** is the critical emerging frontier:
+- Glycosyltransferases (GalT, GnTI, SiaT) immobilized via biotin-streptavidin or CLEA cross-linking → scalable polysaccharide intermediate synthesis with reusability and reduced substrate promiscuity.
+- Lipase-catalyzed desymmetrization of GalNAc precursors → fewer synthetic steps, better atom economy.
+- Immobilized nucleases (RNase T1, P1) and phosphatases → critical QC for duplex assembly verification.
+
+**Dual-target architectures** impose new constraints: extended payloads (50-70 nt) demand higher GalNAc cluster valency; branched dendritic scaffolds and triazole linkers add synthetic complexity. **Industrial-scale CuAAC remains bottlenecked by copper toxicity and solvent requirements** — SPAAC and enzyme-catalyzed ligation are the most promising next-generation alternatives.
+
+---
+
+## Group D — Upstream Supply Chain & Domestic Substitution Opportunities
+
+### Keywords
+- **EN**：oligonucleotide CDMO capacity, phosphoramidite monomers (Hongene/ChemGenes/Ajinomoto), CPG solid support (Prime Synthesis/Kinovate/Nitto), industrial enzymes (NEB/Takara/Codexis/Vazyme), GalNAc ligand suppliers, BIOSECURE Act, IRA reshoring
+- **ZH**：兆维 Hongene, 金斯瑞 GenScript, 诺唯赞 Vazyme, 凯莱英 KaiLai, 药明康德 WuXi, 博腾, 九洲, 锐博生物, 小核酸 CDMO, 国产替代, 固相载体, 工业用酶, 亚磷酰胺
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_D02 | Synthesis of GalNAc-Oligonucleotide Conjugates (PNAS primary protocol) | PNAS | 2021 | 1 | 8.4 |
+| src_D13 | Advanced siRNA Design & 2'-F/2'-OMe monomer optimization | Nat Biotechnol | 2019 | 1 | 8.2 |
+| src_D03 | Bioconjugated Oligonucleotides: phosphoramidite chemistry + suppliers | Sem Cell Dev Biol | 2019 | 1 | 8.1 |
+| src_D14 | BIOSECURE Act becomes law (2025 NDAA §851) | Arnold & Porter | 2025 | 1 | 7.8 |
+| src_D06 | Codexis ECO Synthesis RNA Manufacturing (>75% yield) | Codexis | 2024-25 | 2 | 7.5 |
+| src_D09 | 兆维 Hongene Shanghai Fengxian commercial base (1 kg/batch, 48 lines) | 医药魔方 | 2025 | 2 | 7.4 |
+| src_D11 | KPMG China Biotech 50 — 兆维/凯莱英/药明 oligo roadmap | KPMG | 2025 | 2 | 7.3 |
+| src_D04 | Prime Synthesis CPG gold standard (LGC Biosearch) | LGC | 2024 | 2 | 7.3 |
+| src_D01 | Evaluate Pharma CDMO Intelligence Report (7.29% CAGR 2023-28) | Evaluate | 2023-26 | 2 | 7.2 |
+| src_D10 | GenScript 2025 results ($959.5M, +61.4% YoY) | HK.1548 filing | 2026 | 2 | 7.2 |
+| src_D05 | NittoPhase HL high-load solid support (40% cost cut) | Kinovate/Nitto | 2025 | 2 | 7.1 |
+| src_D15 | Phosphoramidite Market (NA 40% share, APAC 7.43% CAGR) | Mordor Intel | 2024 | 2 | 7.0 |
+| src_D08 | Codexis T7 RNA polymerase / ligation services | Codexis | 2025 | 2 | 6.9 |
+| src_D12 | Smartanalyst China Oligo CDMO 2025-2030 | 腾讯/医药魔方 | 2025 | 2 | 6.9 |
+| src_D07 | Takara RNase H / DNase I / T7 RNAP GMP-grade (Kusatsu) | Takara | 2024 | 2 | 6.8 |
+
+### Direction Summary (EN)
+
+The dual-target siRNA upstream supply chain shows **three high-value choke points** with largest domestic-substitution windows:
+
+**1. Phosphoramidite monomers** — 2'-OMe, 2'-F, GalNAc-phosphoramidite supply concentrated in Ajinomoto Bio-Pharma, ChemGenes, Hongene (兆维). Hongene already achieves 98% purity oligo API at 1 kg/batch with 48-line capacity and NMPA+FDA+EMA QA. Domestic R&D under "十四五" biotech localization targets projects 30-50% import-reliance reduction by 2027.
+
+**2. Solid supports (CPG & polymeric)** — Gold-standard CPG dominated by LGC Biosearch (Prime Synthesis); Nitto Denko's NittoPhase HL offers 40% raw-material cost advantage at 350-400 µmol/g loading. Chinese CDMOs have capital access to catch up quickly; geographic diversification (US + EU + JP) is built in at Tier 2 suppliers.
+
+**3. Industrial enzymes & cell-free systems** — T7 RNA polymerase, RNase H, RNA ligase bottlenecks are being attacked by Codexis (engineered variants), Takara GMP nuclease (Kusatsu), NEB PURExpress. **BIOSECURE Act (Dec 2025)** restricts WuXi, BGI, Complete Genomics from U.S. federal contracts — forcing diversification to Japan, Europe, India; a **18-36 month capacity-deficit window** opens a $200-400M domestic-substitution opportunity in NA/EU through 2028.
+
+---
+
+## 交叉发现（Cross-Group Insights）
+
+1. **Alnylam + Arrowhead 主导设计范式 vs. 中国主导规模化工艺**：海外赢在分子设计 IP（US9187746 等），国内兆维 Hongene 赢在 GMP 规模化和工艺复刻速度；Sirnaomics、瑞博、舶望、必贝特构成国内设计端第二梯队。
+2. **Codexis 酶法路线贯穿 B/C/D 组**：其 ECO Synthesis 平台同时被 Bachem、Nitto Denko Avecia、RNA CDMO 采纳，是酶催化替代传统固相最关键的"上游供应商×工艺平台"双重节点。
+3. **NMPA 2026 draft 指导原则（src_B18）**是关键监管变量：首次将化学酶连合成法列入正式 CMC 指导范围，与 BIOSECURE Act 形成"中国给工艺放行、美国给供应商关门"的对冲格局。
+4. **多价 GalNAc + 酶法偶联** 是下一代双靶点 siRNA 的工艺交汇点：A 组的 Sirnaomics muRNA、瑞博 RiboGalSTAR™、舶望 RADS 平台，都需要 C 组描述的高价态 GalNAc 簇 + 固定化糖基转移酶配套，D 组需要对应的三触角 GalNAc 单体与 CuAAC/SPAAC 催化剂供应。
+
+---
+
+## 识别的关键数据缺口（Phase 2 需补）
+
+- 各家双靶点管线的 **具体合成工艺细节**（固相 vs. 液相 vs. 酶连）在公开文献中披露度不均 → Phase 2 需从专利说明书补
+- 国内企业 **亚磷酰胺单体国产化率** 的定量数据仅见于券商研报（Tier 2），需交叉 NMPA/进出口数据
+- **固定化酶用于 siRNA 偶联** 的工业案例偏少（学术层面多） → Phase 2 需深挖 Codexis 专利、GreenLight 工艺包
+- **双靶点 siRNA 的分离纯化工艺**（IEX、HIC、离子对 RP-HPLC 对支架分子的选择性）基本空白 → Phase 2 独立深研
+
+---
+
+**下一步**：dr-plan 据此生成 `framework.md`（8-10 章双语大纲），等用户确认后进 Phase 2。

projects/dual-target-rnai-pipeline-2026/phase1/interview.md

@@ -0,0 +1,86 @@
+# Phase 1 访谈记录 · dual-target-rnai-pipeline-2026
+
+- **访谈日期**：2026-04-21
+- **主导 agent**：dr-plan (Claude Opus 4.7)
+- **用户输入命令**：`/dr-init 双靶点RNAi药物研发进展和国内外在研管线`
+
+---
+
+## 1. 主题解析
+
+- 用户原始主题：**双靶点 RNAi 药物研发进展和国内外在研管线**
+- 生成 slug：`dual-target-rnai-pipeline-2026`
+- 项目根目录：`projects/dual-target-rnai-pipeline-2026/`
+
+## 2. 初始边界追问（dr-plan 提出）
+
+为厘清"双靶点"的语义边界，dr-plan 指出其可能的三种定义：
+
+1. 同一条 siRNA 链同时沉默两个基因（共价偶联/串联）
+2. 一个制剂中混配两条 siRNA（cocktail / fixed-dose combination）
+3. 多价 GalNAc 骨架挂载多条 siRNA
+
+并提出 8 个标准问题。
+
+## 3. 用户回答（原话记录）
+
+| # | 问题 | 用户回答 |
+|---|------|---------|
+| 1 | 研究类型 | **A — 综述类（≥10,000 字）** |
+| 2 | 核心受众 | **研发团队** |
+| 3 | 时间范围 | **近 5 年** |
+| 4 | 地理范围 | **全球对比** |
+| 5 | 必须回答的核心问题 | 国内外在研双靶点 RNAi 管线及关键技术壁垒，**尤其是序列合成、偶联化学等** |
+| 6 | 竞争/对比对象 | **全面分析，主要是分析这些公司工艺特点**，挖掘其中供应链的机会，例如**工业用酶原料、无细胞表达、固定化酶催化**等 |
+| 7 | 禁区 | **聚焦原理和工艺，不展开讨论适应症**，报告对象是**上游供应链** |
+| 8 | 字数期望 | **auto** |
+
+## 4. dr-plan 的关键解读（与用户对齐）
+
+用户真实诉求并非标准"药企管线研究"，而是**上游供应链视角的工艺解构报告**：
+- 表层：双靶点 RNAi 的研发进展与管线
+- 内核：通过管线倒推各家**合成与偶联工艺特点** → 识别**上游供应链机会**
+- 受众：上游原料 / 酶 / 工艺研发团队
+- 禁区：适应症与临床数据仅作进度标签
+- 字数：综述 auto = ≥10,000 中文字 / ~7,000 英文词
+
+此解读已在 Step 4 候选标题中显式化，用户选择候选 A 表示认可该定位。
+
+## 5. 候选报告标题（dr-plan 提议）
+
+### 候选 A（推荐 —— 用户最终选定 ✅）
+- **主标题**：《双靶点 RNAi 药物工艺图谱与上游供应链机会研究》
+- **副标题**：近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）
+- 推荐理由：直接暴露"工艺图谱 + 供应链机会"两个核心落点；副标题把用户关心的工业用酶、无细胞表达、固定化酶全部框进去；时间范围显性化。
+
+### 候选 B
+- 主标题：《双靶点 siRNA 合成与偶联工艺深度综述》
+- 副标题：从全球在研管线反推上游酶、原料与规模化催化的产业化机会
+
+### 候选 C
+- 主标题：《双靶点 RNAi 产业链上游机会白皮书》
+- 副标题：工业酶、无细胞表达与固定化催化在下一代寡核苷酸药物中的卡位战（2021–2026）
+
+## 6. 用户选择
+
+> **A**
+
+最终报告标题：
+
+- **主标题**：双靶点 RNAi 药物工艺图谱与上游供应链机会研究
+- **副标题**：近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）
+
+## 7. 字数预算计算（按 length-budget skill）
+
+- 研究类型：综述类 → 基准 10,000 中文字
+- 字数模式：auto → 采用基准 × 1.2 作为目标（给后续发散空间），× 1.0 作为下限
+- **目标字数**：12,000 中文字 / ≈ 8,600 英文词
+- **最低字数**：10,000 中文字 / ≈ 7,150 英文词
+- 工作语言：English（Phase 2-3）
+- 输出语言：中文（Phase 4 翻译）
+
+## 8. 下一步
+
+- ✅ 已创建 `manifest.json`
+- ✅ 已创建目录骨架（phase1-4）
+- ⏭️ 等待用户运行 `/dr-frame` 触发 Phase 1 框架规划（双语大纲）